$53.60
0.861.63%
At close: -
$53.60
0.000.00%
After Hours: Dec 20, 4:04 PM EDT
Comments
Loading...
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock, Earnings Estimates, EPS, And Revenue
Crinetics Pharmaceuticals reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Feb 26
EPS Estimate
$-0.900
Quarterly Revenue Estimate
$700K
Annual Revenue
(as of Sep 30)
(as of Sep 30)
$1M
Analyze the earnings history of Crinetics Pharmaceuticals using advanced sorting and filters.
Data brought to you by Benzinga APIs
Crinetics Pharmaceuticals (CRNX) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Sep 2024 | 2024-11-12 | $-0.96 | $-0.91 | -5.49 % |
| Jun 2024 | 2024-08-08 | $-0.94 | $-0.86 | -9.30 % |
| Mar 2024 | 2024-05-09 | $-0.93 | $-0.81 | -14.8 % |
| Dec 2023 | 2024-02-28 | $-0.90 | $-0.86 | -4.65 % |
Crinetics Pharmaceuticals (CRNX) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Sep 2024 | 2024-11-12 | $0 | $240.00K | -100.0 % |
| Jun 2024 | 2024-08-08 | $399.00K | $460.00K | -13.3 % |
| Mar 2024 | 2024-05-09 | $640.00K | $260.00K | 146.2 % |
| Dec 2023 | 2024-02-28 | $0 | $260.00K | -100.0 % |
FAQ
When is Crinetics Pharmaceuticals (NASDAQ:CRNX) reporting earnings?
Crinetics Pharmaceuticals (CRNX) is scheduled to report earnings on February 26, 2025. The last reported earnings were for reported on November 12, 2024 for Q3.
What were the latest earnings per share (EPS) for Crinetics Pharmaceuticals (NASDAQ:CRNX)?
The Actual EPS was $-0.96, which missed the estimate of $-0.91.
What were Crinetics Pharmaceuticals’s (NASDAQ:CRNX) revenues?
The Actual Revenue was $0K, which missed the estimate of $240K.
Browse earnings estimates, EPS, and revenue on all stocks.